Physicians' Academy for Cardiovascular Education

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome

Video navigation menu

  • Why LDL-C as target to reduce residual risk? 00:14
  • Why do we need further LDL-C lowering therapies? 02:32
  • The promise of PCSK9-inhibiting therapies 03:55
  • Ongoing phase III trials with PCSK9 inhibitors including ACS patients 09:45
  • The relation between PCSK9 inhibition and inflammation 10:10
  • Take home messages 13:48

Educational information

The educational objectives of this symposum were to:

Disclosures

Prof. Erik Stroes, MD: - Chairman, Department of Vascular Medicine, Academic Medical Center, University of Amsterdam - Amsterdam, The Netherlands

Funding

This EBAC accredited symposium was funded by unrestricted educational grants received from Novartis, MSD, Amgen

View slides of this lecture